Study Evaluating the Tolerance of Conjugate Meningococcal C Vaccine in Infants

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 1997
Infant phase: To determine the safety of and production of antibodies by a group C meningococcal conjugate vaccine (MnCC), when given at 2, 3, and 4 months of age with routine vaccines. Booster phase: To compare the safety of and production of antibodies by MnCC with and without MMR and to compare the antibody response to that produced by a low dose of plain polysaccharide vaccine as a way of investigating immune memory
Epistemonikos ID: 979e5af03fe33dbf931a78e826a6e0fac5b1850a
First added on: May 04, 2024